Bright Minds Biosciences Inc.

Bright Minds Biosciences Inc.

DRUGNYSE / NASDAQHealthcareSmall cap

$20.40-$0.30 (-1.4%)

Last close · Data as of Nov 20, 2026

Market cap
$731.0M
P/E
-59.8x
EV / EBITDA
-46.8x
Revenue
$0.00
ROCE
-17.0%

This period includes a one-day price step on 2 Nov 2026 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.

Bright Minds Biosciences Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
Hidden
3M
Hidden
6M
Hidden
1Y
Hidden
5Y
Hidden
  • This period includes a one-day price step on 2 Nov 2026 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.

52-week range

This period includes a one-day price step on 2 Nov 2026 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.

Day change -$0.30 (-1.4%) from $20.70 to $20.40 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in DRUG, bought on each weekday since 2021.

News & filings

What Bright Minds Biosciences filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 12.2 million US dollars in fiscal 2025.

Strengths (1)

  • Current assets are more than ten times current liabilities.
  • Revenue is too small for margins and growth rates to be read, so those points are not shown.
  • This period includes a one-day price step on 2 Nov 2026 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States.

Read moreShow less

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company's BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York.

Sector
Healthcare
Shares outstanding
7.6M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$731.0M
P/E
-59.8x
P/B
8.9x
EV / EBITDA
-46.8x
52-week high
Hidden
52-week low
Hidden

Profitability

ROE
-14.9%
ROCE
-17.0%
ROA
-14.5%

Growth

Revenue
$0.00
Net profit growth, 1Y
336.5%
Free cash flow
-$8.7M

Solvency

Current ratio
36.10
Debt / Equity
0.00
Debt / Assets
0.00
CFO / Net profit
0.71
Cash / Market cap
11.3%

Revenue and net profit

Annual revenue, with net profit as the dashed line.

Bright Minds Biosciences Inc. revenue and net profit by fiscal year
Bright Minds Biosciences Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$0.00-$15.0M
FY2023$0.00-$7.4M
FY2024$0.00-$2.8M
FY2025$0.00-$12.2M

Cash flows

FY2025: -$8.7M from operations, -$8.7M free after investment (dashed).

Bright Minds Biosciences Inc. operating and free cash flow by fiscal year
Bright Minds Biosciences Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$13.6M-$13.6M
FY2023-$7.0M-$7.0M
FY2024-$1.9M-$1.9M
FY2025-$8.7M-$8.7M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$0.00
EBITDA
-$13.9M
Net profit
-$12.2M
Cash from operations
-$8.7M
Free cash flow
-$8.7M
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$0.00-$13.9M-$12.2M-$8.7M-14.9%—+336.5%

Monthly returns

Month-by-month returns of DRUG across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$84.4M
Liabilities$2.4M
Equity$82.0M
Retained earnings-$46.6M

Market cap against peers

8 peers: same sector, nearest by size.

  1. EVMN$745.2M
  2. Bright Minds Biosciences Inc. (this company)$731.0M
  3. CBLL$711.4M

Peers map

Healthcare companies placed by value, growth and quality; DRUG highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

EV / Sales, for the companies without earnings

  1. EVMN54.1x
  2. CBLL7.8x

Not shown (no positive earnings and no EV / Sales): Bright Minds Biosciences Inc., Omeros Corporation, Solid Biosciences Inc., Allogene Therapeutics, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Bright Minds Biosciences Inc.DRUGthis company$731.0M-59.8x8.9x-14.9%-46.8x
BioAge Labs, Inc.BIOA$756.6M-9.4x2.8x-29.6%-7.2x
EVMNEVMN$745.2M-10.8x3.6x-33.5%-8.8x
Omeros CorporationOMER$741.8M-221.4x-6.1x2.8%-8.0x
HealthStream, Inc.HSTM$738.9M40.3x2.1x5.2%11.3x
Solid Biosciences Inc.SLDB$712.8M-4.1x4.0x-96.8%-3.8x
CBLLCBLL$711.4M-13.3x4.6x-34.4%-13.8x
Enhabit, Inc.EHAB$706.9M-153.7x1.3x-0.9%20.1x
Allogene Therapeutics, Inc.ALLO$704.1M-3.7x2.4x-65.3%-4.1x
Peer median—-10.1x2.6x-31.6%-5.7x

Year-to-date ROI

DRUG since 1 January, against earlier years.

Historical volatility

DRUG's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

LineFY2025
Operating expensesOperating Expense$13.9M
Research and developmentResearch And Development$11.1M
Other operating expensesOther Operating Expenses$290.0k
Total expensesTotal Expenses$13.9M
Operating incomeOperating Income-$13.9M
Pretax incomePretax Income-$12.2M

Learn while you research

Academy chapters picked for Bright Minds Biosciences Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →